Merck Sharp + Dohme Corp.

Janssen Pharmaceutica Nv

Aicuris Anti-infective Cures Gmbh

Bangping Xiang

Kevin Michael Belyk

Nobuyoshi Yasuda

Guy R Humphrey

Jianguo Yin

Yue-Mei Zhang

Wilfried Schwab

Richard John Varsolona

Hongmei Li

Shen-Chun Kuo

Peter Emmanuel Maligres

Kevin Campos

Zhuqing Liu

Edward Cleator

Lawrence J Wilson

Shyh-Ming Yang

Kenneth Rhodes

Michael J Zacuto

Cheng Yi Chen

Alexei Kalinin

Robert Scannevin

Jingjun Yin

Paul F Jackson

Xiaodong Fan

Prabha Saba Karnachi

Burkhard Klenke

Tetsuji Itoh

Kelvin Yong

Melodie Deniz Christensen

Matthew Thomas Tudge

Michael R Luzung

Andrew Brunskill

Davraj Chakravarty

Stephen Mark Dalby

Tom Moody

Gareth Brown

Jongrock Kong

Sarah Dolman

Kevin M Belyk

The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention. 

Process for preparing substituted tetracyclic heterocycle compounds

The present invention is directed to a process for making Substituted Quinazoline Compounds of formula (I): which are useful for the treatment and prophylaxis of HCMV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I). 

Process for making substituted quinazoline compounds

The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine, utilizing a highly effective spiroacid synthesis.

Process for making CGRP receptor antagonists

The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts.

Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts

The present invention relates to macrolactam compounds, intermediates useful in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing and modifying macrolactams. One use of the compounds and methods described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. An example of an HCV inhibitory compound that can be synthesized using the procedures described herein is Compound A and derivative thereof.

Process and intermediates for preparing macrolactams

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Heterocyclic derived metalloprotease inhibitors

Growing community of inventors

Bridgewater, NJ, United States of America

Bangping Xiang